Bioventus Inc. (BVS) vs Corvus Pharmaceuticals, Inc. (CRVS)

A side-by-side comparison of Bioventus Inc. and Corvus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — BVS vs CRVS

growth of $100 · dividends reinvested · last 6y
BVS -29.6% (-5.7%/yr)CRVS +158.8% (+17.2%/yr)CRVS compounded faster over this window
0200400600Start $10020222023202420252026$70$259
BVS CRVS

BVS vs CRVS: by the numbers

  • •BVS is the larger company ($897M vs $875M market cap).
  • •BVS is profitable (9.36% net margin) while CRVS runs a net loss (0.00%).

Metrics side by side

Valuation

MetricBVSCRVS
P/E ratio17.18N/A
Forward P/E17.00N/A
P/S ratio1.54N/A
P/B ratio3.933.88
EV / EBITDA10.56N/A
FCF yield10.51%N/A

Profitability

MetricBVSCRVS
Gross margin68.00%0.00%
Operating margin10.63%0.00%
Net margin9.36%0.00%
ROE23.86%-24.02%
ROIC11.37%-25.25%

Growth (annualized)

MetricBVSCRVS
Revenue CAGR (5Y)11.82%N/A
EPS CAGR (5Y)-5.03%N/A
FCF CAGR (5Y)43.36%N/A
Total return CAGR (5Y)-0.81%17.88%

Frequently asked

Is BVS or CRVS more profitable?
BVS runs the higher net margin — BVS at 9.36% versus CRVS at 0.00%.
How have BVS and CRVS total returns compared?
Over the past 5 years, BVS delivered -0.81% and CRVS delivered 17.88% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.